Composition used for removal of fusobacterium and / or streptococcus bacteria

Abstract

To provide a novel technique for removal of Fusobacterium and / or Streptococcus bacteria.SOLUTION: The foregoing problem is solved by a composition for removal of Fusobacterium and / or Streptococcus bacteria, containing platinum nanoparticles and / or electrolyzed water as an active ingredient.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a composition used for removing Fusobacterium and / or Streptococcus bacteria, treating or preventing diseases caused by these bacteria, and treating or preventing colorectal cancer, esophageal cancer, inflammatory bowel disease, infective endocarditis, bacteremia, periodontal disease or dental caries. [Background technology]

[0002] Fusobacterium is a bacterium that mainly lives in the oral cavity and is known to cause periodontal disease, but recent research has revealed that it is also involved in a variety of diseases.

[0003] Since the early 2010s, numerous reports have emerged suggesting that Fusobacterium nucleatum may be related to the carcinogenesis of colorectal cancer (e.g., Non-Patent Document 1). The mechanism by which Fusobacterium nucleatum is related to carcinogenesis is said to be related to FadA and Fap2 expressed by Fusobacterium nucleatum. It is also thought to be related to the progression of colorectal cancer by evading lymphocyte attacks on cancer cells and by avoiding apoptosis. Furthermore, Fusobacterium nucleatum is related to the promotion of cell proliferation, and the effect of overexpression of microRNA on cancer suppressor genes has also been discussed (Non-Patent Document 2).

[0004] Inflammatory bowel disease (IBD) is broadly classified into ulcerative colitis (UC) and Crohn's disease (CD), and has been said to be an autoimmune disease in which inflammatory cells, mainly lymphocytes, attack the intestinal mucosa of the patient due to immune abnormalities, causing inflammation and ulcers. However, the theory that IBD is an intestinal bacterial infection has become popular based on the following facts: spontaneous immune abnormality enteritis does not develop in a sterile environment; there are abnormally many bacteria in the intestinal mucosa of IBD patients; bad bacteria are more prevalent than good bacteria in the intestinal flora compared to normal people; gene polymorphism analysis has revealed that there are many gene polymorphisms in IBD patients that are linked to a decrease in the bacterial elimination mechanism and mucosal defense mechanism; tolerance to intestinal bacteria is decreased in IBD patients, causing excessive immune reactions (inflammation); and Toll-like receptor (TLR), the main component of natural immunity, is expressed in the intestinal epithelium, and many of them use bacteria as ligands (Non-Patent Document 3).

[0005] More specifically, it has been reported that the detection rate of Fusobacterium varium in the inflamed mucosa of UC patients is significantly higher than that of healthy individuals, and that serum antibody titers are also significantly higher in UC patients. Furthermore, using immunohistochemical staining, it has been demonstrated that Fusobacterium varium is present at a higher rate in the inflamed mucosa than in patients with other diseases or healthy individuals (Non-Patent Document 4).

[0006] Furthermore, Fusobacterium varium exhibits cytotoxicity to Vero cells despite the lack of the Verotoxin gene. This is because the butyric acid produced by this bacterium is cytotoxic to Vero cells. It has been reported that the butyric acid produced by this bacterium induces apoptosis and induces UC-like lesions in mice (Non-Patent Document 5). Furthermore, it has been confirmed that Fusobacterium varium adheres to and invades colonic mucosal cells, and has the effect of significantly promoting the production of inflammatory cytokines such as IL-8 and TNFα from the mucosa (Non-Patent Document 6). Based on the above, it is believed that this bacterium induces inflammation in addition to ulcers, causing ulcerative colitis. It has been reported that when Fusobacterium varium antibody-positive UC patients were administered three antibiotics (amoxicillin, tetracycline, and metronidazole; ATM therapy) that are sensitive to the bacteria in order to eradicate Fusobacterium varium, the symptoms of UC and the endoscopic and histopathological findings improved (Non-Patent Document 7). A similar report was also made in a multi-center, double-blind, placebo-controlled study of over 200 patients (Non-Patent Document 8). Based on the above, Fusobacterium varium is thought to be the causative agent of UC.

[0007] Fusobacterium nucleatum has also been cited as a causative bacterium of CD (Non-Patent Document 3). It has been reported that the bacterium was detected in endoscopic biopsy mucosa of CD in 10 of 17 cases (58.8%), and all of them were invasive (Non-Patent Document 9).

[0008] Fusobacterium nucleatum has also been reported to be associated with esophageal cancer. Specifically, it has been reported that Fusobacterium nucleatum is present in significantly greater amounts in esophageal cancer tissue than in normal esophageal mucosa, that the bacterium is significantly associated with tumor stage, and that a significant relationship between the bacterium and the chemokine CCL20 has been observed, suggesting that the bacterium contributes to the aggressive behavior of tumors through the activation of chemokines such as CCL20 (Non-Patent Document 10).

[0009] Fusobacterium prausnitzii is attracting attention as a probiotic that consumes acetic acid, produces butyric acid, which is beneficial for health, and improves intestinal barrier function. It has been reported that the occupancy level of this bacterium is reduced in both feces and mucosal samples of CD patients and that this bacterium is associated with inflammatory bowel disease (Non-Patent Document 11). It has also been reported that administration of this bacterium to mice has an inhibitory effect on the onset of inflammatory bowel disease (Non-Patent Document 12).

[0010] Streptococcus mutans, a major pathogenic bacterium in dental caries, is known as a causative bacterium of bacteremia and infective endocarditis, but recent research has revealed that it also induces the exacerbation of inflammatory bowel disease. Observation of the abdominal cavity of mice intravenously injected with the bacterium showed signs of enteritis, and administration of the bacterium into the blood of a mouse enteritis model caused the enteritis to worsen. It has been reported that the mechanism behind this is that in strains of the bacterium with a mutation in the surface polysaccharide antigen, this leads to a decrease in phagocytosis by white blood cells, leading to the acquisition of properties that make it difficult to eliminate in the blood for a long time, and that another important factor is that the collagen-binding protein present on the bacterial surface causes the bacterium to localize in liver tissue and be directly taken up by liver parenchymal cells (Non-Patent Document 13). It has been suggested that this promotes the production of cytokines such as IFN-γ, which induces an imbalance in the immune system and induces the exacerbation of inflammatory bowel disease.

[0011] In addition, it has been reported that infective endocarditis caused by Streptococcus bovis is frequently associated with colon cancer (Non-Patent Documents 14-22), and a report has been published suggesting that the presence of bile acids leads to carcinogenesis by promoting colony formation in place of enterococci (Non-Patent Document 22). It has also been suggested that the cell wall extracted antigen (WEA) of the bacterium stimulates the production of IL-8 and COX-2 in Caco-2 cells, which are human colonic epithelial cells, and causes phosphorylation of mitogen activated protein (MAP) kinase, and that the overproduced COX-2 induces cancer induction from a precancerous state through prostaglandin production, cell proliferation, angiogenesis, and apoptosis inhibition (Non-Patent Documents 23-25). It has also been shown that WEA strongly promotes precancerous lesions in azoxymethane-administered mice (Non-Patent Document 26). Furthermore, it has been reported that this bacterium strongly promotes colorectal adenomas to colorectal cancer by inducing NF-κB (Non-Patent Document 27).

[0012] Streptococcus anginosus, which is also detected in endocarditis, is said to be a risk factor for esophageal cancer. It has been reported that the bacterium has been detected in esophageal cancer tissue, and that the risk of esophageal cancer increases by approximately 33 times when Streptococcus anginosus is detected in dental plaque in a comparison between esophageal cancer patients and normal subjects (Non-Patent Document 28). [Prior art documents] [Non-patent literature]

[0013] [Non-Patent Document 1] Genome Res.2012;22:299-306 [Non-Patent Document 2] Journal of Enterobacteriaceae 35:1-11,2021 [Non-Patent Document 3] Modern Media Vol. 60, No. 11, 2014 [Intestinal flora] 325 [Non-Patent Document 4] J.Gastroenterol.Hepatol.,2002;17:849-853. [Non-Patent Document 5] GUT,2003;52:79-83. [Non-Patent Document 6] Int. J. Cancer, 1995;27:400-406. [Non-Patent Document 7] Scand J Gastroenterol 2005;40:1334-1342. [Non-Patent Document 8] Trial.Am J Gastroenterol.2010;105:1820-1829. [Non-Patent Document 9] Inflammatory Bowel Diseases 2011;17:1971-1978. [Non-Patent Document 10] Clin Cancer Res (2016) 22 (22): 5574-5581. [Non-Patent Document 11] Frontiers in Microbiology 8: 1889. (2017-09-29) [Non-Patent Document 12] Medical Science Digest October 2019 Special Issue [Non-Patent Document 13] Journal of Pediatric Dentistry 52(4): 471-479 2014 471 [Non-Patent Document 14] N Engl J Med 1977; 297: 800-803. [Non-Patent Document 15] Arq Gastroenterol,2002; 39: 177-180. [Non-Patent Document 16] J Med Assoc State Ala 1951; 162-166. [Non-Patent Document 17] Jpn J Int J 1989;78:835-839. [Non-Patent Document 18] Arch Surg 2004;139:760-765. [Non-Patent Document 19] Treatment 2008; 90: 96-100. [Non-Patent Document 20] Am J Cardiol 2001; 88: 871-875. [Non-Patent Document 21] Clin Infect Dis 2004;38: 1394-1400. [Non-Patent Document 22] Cytokine 2000;12:26-31. [Non-Patent Document 23] Proc Natl Acad Sci USA 115:E283-E291,2018. [Non-Patent Document 24] J. Exp. Clin. Cancer Res. 2011;30:1-1 [Non-Patent Document 25] Lancet Oncol. 2011;12:504-12. [Non-Patent Document 26] Carcinogenesis. 2004;25:1477-8 [Non-Patent Document 27] BMC Cancer. 2009;19:40 [Non-Patent Document 28] Cancer Vol.127,Issue 4,February 15,2021,pp512-519 [Non-Patent Document 29] Microorganisms 2022, 10(3), 664 Summary of the Invention [Problem to be solved by the invention]

[0014] Recent research has revealed that enterobacteria are deeply involved in colon cancer, inflammatory bowel disease, and esophageal cancer. Fusobacterium bacteria, which are widely known as periodontal disease bacteria, and Streptococcus bacteria, which are widely known as causative bacteria of dental caries, infective endocarditis, and bacteremia, have attracted attention as causative bacteria of these diseases. In view of the above, the present invention aims to provide a novel technique for removing Fusobacterium bacteria and / or Streptococcus bacteria. [Means for solving the problem]

[0015] Through the diligent research and efforts of the present inventors, it was discovered for the first time that platinum nanoparticles and electrolytic water have the effect of removing Fusobacterium and Streptococcus. The present invention was completed based on this new discovery, and is specifically as follows.

[0016] [1] A composition used for removing Fusobacterium and / or Streptococcus, comprising platinum nanoparticles and / or electrolyzed water as active ingredients. [2] The composition described in [1], which is further used to promote the growth of bacteria of the genus Faecalis. [3] A composition used for the treatment or prevention of diseases caused by Fusobacterium and / or Streptococcus, comprising platinum nanoparticles and / or electrolyzed water as active ingredients. [4] A composition used for the treatment or prevention of colorectal cancer, inflammatory bowel disease, esophageal cancer, infective endocarditis, bacteremia, periodontal disease or dental caries, comprising platinum nanoparticles and / or electrolyzed water as active ingredients. [5] The composition described in [4], wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease. [6] A composition described in any one of [1] to [5] for administration to a carrier of Fusobacterium and / or Streptococcus. [7] The composition described in [6], wherein the carrier is a person who has Fusobacterium and / or Streptococcus in the oral cavity and / or a person who has Fusobacterium and / or Streptococcus in the intestines. [8] The composition according to any one of [1] to [7], wherein the platinum nanoparticles are dispersed in the electrolyzed water. [9] The composition described in any one of [1] to [8], which is a drinking composition or a mouthwash composition. Effect of the Invention

[0017] According to the present invention, it is possible to remove Fusobacterium and / or Streptococcus bacteria, and to obtain therapeutic or preventive effects against diseases caused by these bacteria, specifically colon cancer, inflammatory bowel disease, esophageal cancer, infective endocarditis, bacteremia, periodontal disease or dental caries. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The composition of the present invention contains platinum nanoparticles and / or electrolyzed water as active ingredients.

[0019] In the present invention, the term "platinum nanoparticles" refers to platinum particles having a diameter of 100 nm or less. Platinum nanoparticles can be produced by any method and device known in the art.

[0020] The average particle size of the platinum nanoparticles is preferably 5 nm or less, more preferably 4.5 nm or less, even more preferably 4 nm or less, and even more preferably 3 nm or less. The average particle size is preferably 0.5 nm or more, more preferably 0.75 nm or more, and even more preferably 1.0 nm or more.

[0021] In this specification, the average particle size is a particle size calculated by a model numerical analysis using a small angle X-ray scattering method.

[0022] Alkaline electrolyzed water is produced when an electrolyte aqueous solution such as a weak saline solution is electrolyzed. In the present invention, it is preferable to use alkaline electrolyzed water produced on the cathode side during electrolysis. The pH of the alkaline electrolyzed water is preferably 8 to 11, more preferably 9 to 10, and even more preferably 9.0 to 9.5.

[0023] When the composition of the present invention contains platinum nanoparticles as an active ingredient, the properties thereof are not particularly limited, and may be liquid, solid, semi-solid, etc. When the composition is in liquid or semi-solid form, the platinum nanoparticles can be prepared by dispersing them in any dispersion medium such as water. When the composition is provided as a solid preparation such as a tablet or capsule, the composition can be prepared by mixing the platinum nanoparticles, which are the active ingredient, with any excipient and molding as necessary.

[0024] When the composition of the present invention is provided as a liquid composition, the concentration of platinum nanoparticles in the entire composition is preferably 0.02 μg / mL or more, even more preferably 0.024 μg / mL or more, and even more preferably 0.03 μg / mL or more. Furthermore, the concentration of platinum nanoparticles in the entire composition is preferably 0.1 μg / mL or less, more preferably 0.096 μg / mL or less, even more preferably 0.09 μg / mL or less, even more preferably 0.08 μg / mL or less, even more preferably 0.076 μg / mL or less, even more preferably 0.07 μg / mL or less, and even more preferably 0.06 μg / mL or less.

[0025] When made into a solid formulation, the content of platinum nanoparticles per tablet is preferably 0.01 mg or more, more preferably 0.016 mg or more, even more preferably 0.02 mg or more, even more preferably 0.024 mg or more, and even more preferably 0.03 mg or more. The content of platinum nanoparticles per tablet is preferably 0.1 mg or less, more preferably 0.096 mg or less, even more preferably 0.09 mg or less, even more preferably 0.08 mg or less, even more preferably 0.076 mg or less, even more preferably 0.07 mg or less, and even more preferably 0.06 mg or less.

[0026] In the case where electrolytic water is used as an active ingredient, the composition of the present invention is preferably in a liquid or semi-solid form. The composition of the present invention may be in a form consisting of electrolytic water itself, or in a form of a mixture with any other liquid or solid ingredient. Drinkable electrolyzed water can be produced using known methods and equipment.

[0027] In a preferred embodiment of the present invention, both platinum nanoparticles and electrolytic water are contained as active ingredients. That is, the platinum nanoparticles may be in the form of a dispersion liquid prepared by dispersing the platinum nanoparticles in electrolytic water. The preferred concentration range of the platinum nanoparticles in the dispersion liquid is as described above.

[0028] The composition of the present invention may be provided in a form that can be prepared immediately before use. That is, the composition may be provided as a kit that includes a first preparation containing platinum nanoparticles and a second preparation containing electrolyzed water. In this case, the composition of the present invention is prepared immediately before use by mixing the first preparation with the second preparation at the time of use.

[0029] The composition of the present invention may contain other known ingredients (flavoring agents, odorants, pH adjusters, excipients, thickeners, fragrances, food colorants, sweeteners, dietary fiber, vitamins, preservatives, antioxidants, etc.) to the extent that the effects of the invention are not impaired.

[0030] The composition of the present invention can be used to remove Fusobacterium. Fusobacterium bacteria that can be removed by the composition of the present invention include Fusobacterium nucleatum and / or Fusobacterium varium.

[0031] The composition of the present invention can also be used to remove Streptococcus. The Streptococcus bacteria to be removed by the composition of the present invention include one or more species selected from Streptococcus mutans, Streptococcus bovis, and Streptococcus anginosus.

[0032] The composition of the present invention can be used for the elimination of Fusobacterium and / or Streptococcus. In a preferred embodiment, the composition of the present invention is used for the elimination of Fusobacterium and Streptococcus.

[0033] The composition of the present invention can also be used to remove Fusobacterium and / or Streptococcus bacteria in the intestine and / or oral cavity. In other words, the composition of the present invention can be used to suppress the occupancy rate of Fusobacterium and / or Streptococcus bacteria in the intestinal flora and / or oral flora.

[0034] The composition of the present invention can also be used to promote the growth of bacteria of the genus Fusobacterium. Examples of bacteria of the genus Fusobacterium whose growth is promoted by the composition of the present invention include Fusobacterium prausnitzii.

[0035] In addition, the composition of the present invention can be used to promote the growth of Faecalibacterium in the intestine. In other words, the composition of the present invention can be used to improve the occupancy rate of Faecalibacterium in the intestinal flora.

[0036] The composition of the present invention can be administered to carriers of Fusobacterium, more specifically Fusobacterium nucleatum and / or Fusobacterium varium. Subjects to whom the composition of the present invention is preferably applied include those who carry Fusobacterium in the intestines and / or oral cavity.

[0037] The composition of the present invention can be administered to a carrier of one or more species selected from the group consisting of Streptococcus mutans, Streptococcus bovis, and Streptococcus anginosus. Subjects to whom the composition of the present invention is preferably applied include those who carry Fusobacterium and / or Streptococcus in the intestines and / or oral cavity.

[0038] Fusobacterium and Streptococcus are known to be pathogens of various diseases. Since the composition of the present invention has an effect of removing Fusobacterium and Streptococcus, the composition of the present invention can be used for treating or preventing diseases caused by Fusobacterium and / or Streptococcus.

[0039] Specifically, the composition of the present invention can be used for the treatment or prevention of colon cancer, inflammatory bowel disease, esophageal cancer, infective endocarditis, bacteremia, periodontal disease, or dental caries. Inflammatory bowel disease to be treated or prevented by the present invention includes ulcerative colitis and Crohn's disease.

[0040] In this specification, "prevention" refers to the act of administering the active ingredient of the present disclosure to a healthy person who has not developed a disease, for example, with the aim of preventing the onset of a disease. "Treatment" refers to the act of administering the active ingredient to a person (patient) who has developed a disease. "Treatment" includes not only fundamental treatment, but also alleviation of symptoms and suppression of disease progression.

[0041] The composition of the present invention can be used for the treatment or prevention of colon cancer, inflammatory bowel disease, esophageal cancer or periodontal disease caused by Fusobacterium bacteria, more specifically, Fusobacterium nucleatum and / or Fusobacterium varium.

[0042] The compositions of the present invention can be used for the treatment or prevention of colon cancer, inflammatory bowel disease, esophageal cancer or periodontal disease by removing Fusobacterium bacteria, more specifically, Fusobacterium nucleatum and / or Fusobacterium varium.

[0043] The composition of the present invention can be used for the treatment or prevention of colon cancer, esophageal cancer, inflammatory bowel disease, infective endocarditis, bacteremia, or dental caries caused by one or more pathogens selected from the genus Streptococcus, more specifically, Streptococcus mutans, Streptococcus bovis, and Streptococcus anginosus.

[0044] The composition of the present invention can be used for the treatment or prevention of colorectal cancer, esophageal cancer, inflammatory bowel disease, infective endocarditis, bacteremia or dental caries by removing one or more species selected from the genus Streptococcus, more specifically, Streptococcus mutans, Streptococcus bovis, and Streptococcus anginosus.

[0045] The composition of the present invention is intended to suppress the intestinal proliferation of Fusobacterium genus bacteria, more specifically Fusobacterium nucleatum and / or Fusobacterium varium, and / or One or more species selected from Streptococcus mutans, Streptococcus bovis, and Streptococcus anginosus are removed, and It can be used for the treatment or prevention of inflammatory bowel disease by promoting the growth of bacteria of the genus Faecalibacterium, more specifically Faecalibacterium prausnitzii.

[0046] Methods that involve administering antibiotics, such as ATM therapy, eliminate not only bad bacteria but also good bacteria, causing side effects such as fever and feeling unwell. On the other hand, the composition of the present invention has the effect of removing the bad bacteria Fusobacterium and Streptococcus, and promoting the growth of the good bacteria Faecalibacterium. In other words, the composition of the present invention has the effect of improving the balance of the intestinal flora, and is therefore advantageous in that it does not cause side effects such as those that occur during antibacterial treatment.

[0047] The composition of the present invention is preferably provided in the form of a drinkable composition or an oral cleaning composition. In particular, when used to remove Fusobacterium and / or Streptococcus bacteria in the intestines, it is preferably provided in the form of a drinkable composition. Furthermore, when used to remove Fusobacterium and / or Streptococcus bacteria in the oral cavity, it is preferably provided in the form of an oral cleaning composition.

[0048] The composition of the present invention having platinum nanoparticles as an active ingredient is preferably ingested so that the daily intake of platinum nanoparticles is 10 μg or more, more preferably 12 μg or more, even more preferably 15 μg or more, even more preferably 18 μg or more, even more preferably 20 μg or more, even more preferably 22 μg or more, even more preferably 25 μg or more, even more preferably 28 μg or more, and even more preferably 30 μg or more. The upper limit of the daily intake of platinum nanoparticles can be set at, for example, 50 μg or less.

[0049] The composition of the present invention containing electrolyzed water as an active ingredient is preferably taken in an amount of 500 mL or more, more preferably 1 L or more per day. There is no particular upper limit to the amount of electrolyzed water that can be taken.

[0050] The period of continuous intake of the composition of the present invention is preferably 1 week or more, more preferably 2 weeks or more, even more preferably 3 weeks or more, even more preferably 4 weeks or more, even more preferably 5 weeks or more, even more preferably 6 weeks or more, even more preferably 7 weeks or more, and even more preferably 8 weeks or more. There is no upper limit on the duration of continuous intake. EXAMPLES

[0051] The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to the following examples.

[0052] Fecal samples were collected from 34 subjects who had installed an alkaline electrolytic water purifier at home and consumed alkaline electrolytic water daily, and the intestinal flora was analyzed by amplicon sequencing targeting the 16s rDNA partial base sequence. The occupancy rates of Fusobacterium, Streptococcus, and Faecalibacterium in the intestinal flora are shown in Table 1 (data in the "1st" row).

[0053] In addition, based on the analytical data of the intestinal bacterial flora, the 34 subjects were classified into the following enterotypes A to E, as defined by the method described in Non-Patent Document 29.

[0054] <Type A> This type is dominated by Ruminococcus. The genus Streptococcus accounts for the second highest proportion of bacteria after type D. <Type B> A type with a high concentration of Bacteroides. The Faecalibacterium content is higher than Type C, which also has a high concentration of Bacteroides, but not significantly higher than Types A, D, and E. A type with a high concentration of butyric acid bacteria. <Type C> Bacteroides is the most abundant type, and Faecalibacterium is the lowest of the five types. Fusobacterium and Proteus are the highest types. <Type D> This type has a significantly high proportion of Bifidobacterium. It also has the highest proportion of Streptococcus among the five types. <Type E> This type is rich in Prevotella and is the type that has the highest number of healthy individuals out of the five types.

[0055] As a result, of the 34 subjects, 6 were classified as type A, 13 as type B, 5 as type C, 3 as type D, and 7 as type E.

[0056] A total of 34 subjects were asked to drink 1.5 L of the above-mentioned alkaline electrolyzed water with platinum nanoparticles dispersed therein per day for 8 weeks. At the end of the drinking period, fecal samples from the subjects were analyzed, and the intestinal flora was analyzed by amplicon sequencing targeting the 16s rDNA partial base sequence. The occupancy rates of Fusobacterium, Streptococcus, and Faecalibacterium in the intestinal flora are shown in Table 1 (data in the "2nd" row).

[0057] The average particle size of the platinum nanoparticles in the dispersion is 2 nm, and 30 μg of platinum nanoparticles are dispersed in 1.5 L of alkaline electrolyzed water. The average particle size of the platinum nanoparticles is calculated by a model numerical analysis using a small-angle X-ray scattering method.

[0058] Table 1 shows the results of analyzing the intestinal flora of 1,803 subjects randomly selected in advance, and the data on the carrier rate (the proportion of subjects who were carriers of the target bacteria among all subjects) and carrier rate (the average value calculated by calculating the occupancy rate of the target bacteria in the intestinal flora of carriers) of Fusobacterium, Streptococcus, and Faecalibacterium (mother data, M data).The results also show the carrier rate and carrier rate obtained from the first and second analyses, as well as the fluctuation rate (the difference obtained by subtracting the previous carrier rate from the subsequent carrier rate, divided by the previous carrier rate and multiplied by 100).

[0059] [Table 1] *1 The rate of change calculated using the carriage rate obtained in the first analysis as the pre-value and the carriage rate obtained in the second analysis as the post-value. *2 The rate of change calculated using the carriage rate in the mother data as the pre-value and the carriage rate obtained in the second analysis as the post-value.

[0060] The carrier rate of Fusobacterium was 0.43% in the mother data, while it was 0.32% in the first analysis after continued consumption of alkaline electrolyzed water (Table 1). If we assume that the carrier rate of the mother data is the initial value, the results shown in Table 1 indicate that alkaline electrolyzed water has the effect of removing Fusobacterium.

[0061] Furthermore, the carriage rate of Fusobacterium was 0.19% in the second analysis after continued ingestion of alkaline electrolyzed water containing dispersed platinum nanoparticles, and considering that the rate of change was significantly lower at -42.70% between the first and second analyses, the results in Table 1 indicate that platinum nanoparticles are effective in removing Fusobacterium.

[0062] The rate of change in Fusobacterium bacteria was -56.98% in "M data vs. the second time" (Table 1). In addition, in the subject group classified as enterotype type C, which is considered to have a particularly high occupancy rate of Fusobacterium bacteria, a rate of change of -100% was achieved in "M data vs. the second time". These results demonstrate that alkaline electrolyzed water with dispersed platinum nanoparticles has a significantly excellent effect in removing Fusobacterium bacteria.

[0063] The carrier rate of Streptococcus was 3.22% in the mother data, and 1.22% in the first analysis after continued consumption of alkaline electrolyzed water (Table 1). If we assume that the carrier rate of the mother data is the initial value, the results shown in Table 1 indicate that alkaline electrolyzed water is effective in removing Streptococcus.

[0064] Furthermore, the carriage rate of Streptococcus was 0.72% in the second analysis after continued ingestion of alkaline electrolyzed water with dispersed platinum nanoparticles, and considering that the rate of change was significantly lower at -40.59% between the "first and second times," the results in Table 1 indicate that platinum nanoparticles are effective in removing Streptococcus.

[0065] The rate of change for Streptococcus was -77.57% in "M data vs. the second test" (Table 1). In addition, in the subject group classified as type D enterotype, which is considered to have a particularly high occupancy rate of Streptococcus, a rate of change of -96% was achieved in "M data vs. the second test," showing the highest rate of change (removal rate) among all enterotypes. These results demonstrate that alkaline electrolyzed water with dispersed platinum nanoparticles exhibits a remarkably excellent effect in removing Streptococcus.

[0066] Additionally, the carrier rate of Faecalibacterium was 5.80% in the mother data, but was 7.42% in the first analysis after continued consumption of alkaline electrolyzed water (Table 1). If we assume that the carrier rate in the mother data is the initial value, the results shown in Table 1 indicate that alkaline electrolyzed water has the effect of promoting the growth of Faecalibacterium.

[0067] In addition, the carrier rate of Faecalibacterium was 85% in the first analysis after continuous drinking of alkaline electrolyzed water, but increased to 91% in the second analysis after continuous drinking of alkaline electrolyzed water with platinum nanoparticles dispersed (Table 1). This result indicates that platinum nanoparticles have the effect of promoting the growth of Faecalibacterium.

[0068] Considering the result that the fluctuation rate of Faecalibacterium spp. was 23.27% in "M data vs. second time", it was shown that alkaline electrolyzed water with dispersed platinum nanoparticles has a significantly excellent effect of promoting the growth of Faecalibacterium spp.

[0069] From the above results, it can be concluded that the composition of the present invention containing platinum nanoparticles and / or electrolytic water as active ingredients has an excellent effect of removing Fusobacterium and Streptococcus. Furthermore, this test showed that the composition of the present invention has a therapeutic or preventive effect on diseases caused by Fusobacterium or Streptococcus, specifically colon cancer, inflammatory bowel disease, esophageal cancer, infective endocarditis, bacteremia, periodontal disease, or dental caries.

[0070] In addition, from the above results, it can be concluded that the composition of the present invention containing platinum nanoparticles and / or electrolytic water as an active ingredient has an excellent effect of promoting the growth of Faecalibacterium spp. Considering that Faecalibacterium spp. is attracting attention as a probiotic for the treatment or prevention of inflammatory bowel disease, it can be said that the composition of the present invention can effectively treat or prevent inflammatory bowel disease by the synergistic effect of removing Fusobacterium spp. and promoting the growth of Faecalibacterium spp. [Industrial Applicability]

[0071] The composition of the present invention can be used industrially as a drinking composition or a mouthwash composition used to remove Fusobacterium and / or Streptococcus.

Claims

1. A composition used for removing Fusobacterium and / or Streptococcus, comprising platinum nanoparticles and / or electrolyzed water as active ingredients.

2. The composition described in claim 1, which is further used to promote the growth of bacteria of the genus Faecalis.

3. A composition used for treating or preventing diseases caused by bacteria of the genus Fusobacterium and / or Streptococcus, comprising platinum nanoparticles and / or electrolyzed water as active ingredients.

4. A composition used for the treatment or prevention of colon cancer, inflammatory bowel disease, esophageal cancer, infective endocarditis, bacteremia, periodontal disease or dental caries, comprising platinum nanoparticles and / or electrolyzed water as active ingredients.

5. The composition of claim 4, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

6. A composition according to any one of claims 1 to 5, for use in administering to a carrier of bacteria of the genus Fusobacterium and / or Streptococcus.

7. The composition described in claim 6, wherein the carrier is a person who has Fusobacterium and / or Streptococcus in the oral cavity and / or a person who has Fusobacterium and / or Streptococcus in the intestines.

8. The composition according to any one of claims 1 to 5, wherein the platinum nanoparticles are dispersed in the electrolyzed water.

9. The composition according to any one of claims 1 to 5, which is a drinkable composition or a mouthwash composition.

Images